| . | Ibrutinib plus RICE/RVICI (n = 35) . | RICE/RVICI (n = 16) . |
|---|---|---|
| Best ORR (CR, CRb, CRu, PR), n (%)‡ | 24 (69) | 13 (81) |
| Best OR, n (%) | ||
| CR§ | 6 (17) | 3 (19) |
| PR | 18 (51) | 10 (63) |
| MR | 4 (11) | 0 |
| SD | 3 (9) | 2 (13) |
| Progressive disease | 1 (3) | 0 |
| No evidence of disease‖ | 1 (3) | 0 |
| Unknown/missing | 2 (6) | 1 (6) |
| . | Ibrutinib plus RICE/RVICI (n = 35) . | RICE/RVICI (n = 16) . |
|---|---|---|
| Best ORR (CR, CRb, CRu, PR), n (%)‡ | 24 (69) | 13 (81) |
| Best OR, n (%) | ||
| CR§ | 6 (17) | 3 (19) |
| PR | 18 (51) | 10 (63) |
| MR | 4 (11) | 0 |
| SD | 3 (9) | 2 (13) |
| Progressive disease | 1 (3) | 0 |
| No evidence of disease‖ | 1 (3) | 0 |
| Unknown/missing | 2 (6) | 1 (6) |
CRb, complete response biopsy-negative; CRu, complete response unconfirmed; ITT, intention-to-treat; MR, minor response; SD, stable disease.
Based on independent committee-confirmed events.
Efficacy based on all randomized patients.
Best overall response will only consider tumor assessment up to subsequent anticancer therapy.
There were no other CR categories.
If no disease observed at baseline, follow-up assessments were described by this classification.